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Abstract
Background—Recent studies have demonstrated the utility of polygenic risk scores (PRSs) for 
exploring the genetic etiology of psychiatric phenotypes and the genetic correlations between 
them. To date, these studies have been conducted almost exclusively using participants of 
European ancestry, and thus, there is a need for similar studies conducted in other ancestral 
populations. However, given that the predictive ability of PRSs are sensitive to differences in 
linkage disequilibrium (LD) patterns and minor allele frequencies across discovery and target 
samples, the applicability of PRSs developed in European ancestry samples to other ancestral 
populations has yet to be determined. Therefore, the current study derived PRSs for cigarettes per 
day (CPD) from predominantly European-ancestry samples and examined their ability to predict 
nicotine dependence (ND) in a Native American (NA) population sample.
Method—Results from the Tobacco and Genetics Consortium’s meta-analysis of genome-wide 
association studies of CPD were used to compute PRSs in a NA community sample (N=288). 
These scores were then used to predict ND diagnostic status.
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Results—The PRS was not significantly associated with liability for ND in the full sample. 
However, a significant interaction between PRS and percent NA ancestry was observed. Risk 
scores were positively associated with liability for ND at higher levels of European ancestry, but 
no association was observed at higher levels of NA ancestry.
Conclusion—These findings illustrate how differences in patterns of LD across discovery and 
target samples can reduce the predictive ability of PRSs for complex traits.
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1. INTRODUCTION
Tobacco use and nicotine dependence (ND) remain highly prevalent in the United States. 
Approximately 16.8% of the U.S. adult population self-identified as current smokers in 
2014, and the majority of these individuals reported smoking at least once daily (Centers for 
Disease Control and Prevention [CDC] 2015). Estimates from nationally representative 
samples of past-year daily smokers indicate that over 60% meet criteria for ND (Donny and 
Dierker, 2007). Continued use of tobacco is the leading cause of preventable disease and 
mortality in the U.S. (U.S. Department of Health and Human Services [USDHHS], 2014), 
and thus represents a significant public health concern (USDHHS, 2010).
Of additional note, epidemiological studies suggest rates of tobacco use and ND differ 
across racial and ethnic groups, indicating that this serious public health issue has a 
disproportionate effect on certain minority groups. Smoking rates in the U.S. are highest 
among American Indian and Alaska Native populations; in 2014, 29.2% of non-Hispanic 
American Indian and Alaska Native individuals smoked cigarettes versus 16.8% in the U.S. 
overall (CDC, 2015). Although prevalence rates differ across tribes within these populations, 
and many sociocultural and economic factors influence these prevalence rates, the high 
proportion of American Indian individuals who report smoking puts this group at a uniquely 
high risk for disease and related negative consequences (USDHHS, 1998).
Quantitative genetics studies estimate that a substantial proportion of variance in the 
diagnosis of nicotine dependence and smoking behavior is due to genetic factors. At a 
population level, twin and family studies have indicated that genetic factors account for 
approximately 44% of the variance in smoking initiation (Vink et al., 2005), 50% of the 
variance in smoking quantity (Mackillop et al., 2010), and 33–75% of the variance in the 
liability for ND (Agrawal and Lynskey, 2008; Agrawal et al., 2012). In Native American 
(NA) populations, the heritability estimates (h2) for regular and persistent tobacco use 
approach similar levels and range from 0.37–0.53 and 0.34–0.46, respectively (Ehlers and 
Wilhelmsen, 2006). As a result, published evidence suggests that these phenotypes are 
similarly heritable across European and NA populations (Ehlers and Gizer, 2013).
Evidence from meta-analyses of genome-wide association studies (GWASs) have identified 
common variants associated with number of cigarettes smoked per day (CPD), including 
those within the nAChR genes on chromosome 15q24-q25 (Chen et al., 2012; David et al., 
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2012; Liu et al., 2010; Saccone et al., 2010; Thorgeirsson et al., 2010; Tobacco and Genetics 
Consortium, 2010; Ware et al., 2011), and variants in regions that contain CYP2A6 and 
CYP2B6 on chromosome 9q13 and CHRNB3 and CHRNA6 on chromosome 8p11 
(Thorgeirsson et al., 2010). Though most of the genome-wide approaches have focused on 
quantitative measures of smoking behavior, ND has also been associated with variants 
within the nAChR genes (Rice et al., 2012; Thorgeirsson et al., 2008) and may account for 
the robust relationships observed between higher levels of self-reported cigarette smoking 
and variants within this region (Rice et al., 2012). Despite these initial successes, it is 
important to note that these efforts have focused almost exclusively on participants of 
European ancestry, thus limiting the generalizations that can be drawn from these studies in 
relation to other ancestral groups, including NA populations.
It is also notable that the amount of variance explained by each SNP identified in the 
described studies fails to approach the heritability estimates reported by quantitative genetics 
studies. This is because complex traits such as smoking behaviors and ND are thought to be 
highly polygenic in nature with hundreds of variants, each of small individual effect (e.g., 
R2<0.005) contributing to the development of the phenotype. Therefore, modeling the 
additive or cumulative effects of associated variants has the potential to explain a higher 
proportion of variation in a trait relative to a single variant. To this effect, methods were 
developed to calculate and test the association of polygenic risk scores (PRSs) with a 
phenotype of interest (The International Schizophrenia Consortium [ISC], 2009; Wray et al., 
2007). Notably, GWASs of common variants suggest that many, if not most, of the variants 
involved in complex trait etiology have too small an effect size to reach genome-wide 
significance levels even when sample sizes are large (∼40,000). Thus, PRSs are typically 
created by selecting variants that achieve a pre-designated significance level (e.g., p<0.01 
rather than p<5 × 10−8) from a large-scale ‘discovery’ GWAS with the assumption that their 
cumulative effect will reduce the influence of spurious associations. Once variants are 
selected, the number of risk alleles at each marker are tallied, weighted by their respective 
regression beta weight or log odds ratio, and summed to create a risk score for each 
individual in an independent replication sample. These risk scores are then used to determine 
the proportion of variation in the trait that can be explained by their cumulative effects.
The application of PRSs to the study of psychiatric phenotypes has been met with a fair 
amount of success. For example, PRSs were able to explain 6% of the variation in 
schizophrenia diagnostic rates, a considerable improvement compared to the variation 
explained by individual variants, which was less than 1% (Ripke et al., 2011). Other 
psychiatric phenotypes (e.g., de Moor et al., 2015; de Zeeuw et al., 2014; Hamshere et al., 
2013a; 2013b; ISC, 2009; Ruderfer et al., 2013; Sklar et al., 2011) have demonstrated 
similar results using cumulative measures of genetic risk, including tobacco and other 
substance use phenotypes (Salvatore et al., 2014). PRSs for variants associated with CPD in 
the Tobacco and Genetics Consortium (TAG) meta-analysis (Tobacco and Genetics 
Consortium [TAG], 2010) significantly predicted tobacco use at ages 20 and 24 (Vrieze et 
al., 2012), and in another study, explained a small but significant proportion of the variation 
in number of drinks consumed per week (0.4–0.5%) and age of cannabis initiation (0.6–
0.9%; Vink et al., 2014). These findings demonstrate the potential of PRS approaches to 
further our understanding of how genetic influences contribute to risk for individual 
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substance use phenotypes, as well as how these genetic influences might contribute to shared 
risk across substances.
Despite these promises, limitations exist in the application and interpretation of findings 
from studies employing PRS methods, including aspects of the discovery sample. Adequate 
sample size is necessary for precise score estimation in the discovery population, and the 
optimal p-value threshold used for selecting score variants from the initial genome-wide 
analysis depends on the size of the discovery sample. With adequately powered discovery 
samples, one can lower the threshold for variant inclusion, as these are more likely to reflect 
true positive associations with the phenotype (Wray et al., 2014). Additionally, disparate 
patterns of linkage disequilibrium (LD) and differences in marker allele frequencies between 
discovery and target samples are thought to attenuate effects in PRS analyses (ISC, 2009; 
Wray et al., 2007).
This last consideration has important implications. Population stratification and differential 
patterns of LD across racial and ethnic groups are well-known confounds that can bias 
results from genetic association studies (Price et al., 2006). The vast majority of GWASs are 
conducted with individuals of European descent, and given that methods for computing 
PRSs depend on summary statistics from GWASs, risk alleles identified from these studies 
may be specific to that ancestral group or include tag single nucleotide polymorphisms 
(SNPs) not found in other populations (Domingue et al., 2014). In addition, a standard 
practice in the construction of PRSs involves the LD-based pruning of GWAS results, so that 
only a single SNP from a given genomic region is included in the PRS. This is accomplished 
by selecting an initial set of SNPs that meet a predefined p-value, and then, beginning with 
the most highly associated SNP and proceeding in order of descending strength of 
association, using LD statistics to iteratively remove correlated markers from the set (e.g., 
R2<0.2 across 500kb; Wray et al., 2014). This procedure ensures that only independent 
association signals are included, and thus, protects against overestimating the explanatory 
power of the PRS (ISC, 2009; Wray et al., 2007).
The existing literature on PRSs for psychiatric phenotypes has been almost exclusively 
restricted to discovery and target samples composed of individuals of European descent. 
Because LD-based clumping procedures are employed in order to restrict the PRS to a set of 
independent signals, one disadvantage to this approach is the reliance on a single SNP to 
effectively tag a region based on its LD with other nearby markers. The extent to which 
these findings would replicate in a sample with different patterns of LD and minor allele 
frequencies is unknown. Given epidemiological data indicating that NA populations have the 
highest rates of smoking and ND of any U.S. ethnic group and the heritability of these traits 
in this population (Wilhelmsen and Ehlers, 2005), validating the predictive ability of PRSs 
for smoking phenotypes in this population is important for understanding the genetic 
contributions to these behaviors. In addition, the availability of larger consortium datasets 
mainly composed of European-ancestry individuals highlights a growing need to address 
disparities in the racial and ethnic populations represented in the psychiatric genetics 
literature. Thus, the current study aimed to evaluate whether a PRS derived from a large-
scale GWAS of CPD conducted in a predominantly European-ancestry sample would 
generalize to, and thus predict tobacco use phenotypes, in a NA population sample.
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2. METHODS
2.1. Discovery Sample from Tobacco and Genetics (TAG) Consortium
The TAG consortium’s GWAS meta-analysis of CPD was composed of European-ancestry 
individuals (N=38,131) drawn from 16 studies (TAG, 2010). Participants who endorsed 
smoking 100 cigarettes in their lifetime were asked to report on either average or maximum 
CPD. Each of the 16 studies performed their own genotyping, quality control, and 
imputation. Further details on the methods and summary statistics for the approximately 2.5 
million markers in common across the 16 studies are reported in the published meta-analysis 
and available for download (http://www.nature.com/ng/journal/v42/n5/full/ng.571.html; 
TAG, 2010).
2.2. Target Sample from Native American (NA) Community Population
Participants were recruited from eight geographically contiguous reservations and eligible 
for participation if they reported at least 1/16th NA heritage, and were between 18 and 82 
years old. The full sample included 775 participants nested within 161 families ranging in 
size from 1 to 319 individuals. Quality control procedures excluded 78 individuals from 
analyses. Sixty-seven samples could not be sequenced due to insufficient or low-quality 
deoxyribonucleic acid (DNA), and 11 samples could not be successfully identified when 
matching kinship coefficients to self-reported pedigree structure. Of the 697 individuals 
remaining, 288 individuals with available sequence and smoking phenotype data were 
selected for the current study. At least 50% NA heritage was reported by 39.6% of 
participants (median percent NA heritage=44.4), based on federal Indian blood quantum. 
Average age of the final sample was 32.7 years (SD=14.9), and predominantly female 
(55.6%; N=160). ND was reported by 37.5% of participants (N=108), and the average CPD 
was 14.1 (SD=12.7).
2.3. Measures
The Semi-Structured Assessment for the Genetics of Alcoholism (SSAGA) was 
administered to assess for CPD and DSM-IV ND, as well as demographic information. The 
SSAGA is an empirically validated semi-structured psychiatric interview with high test-
retest reliability (kappas=0.70–0.90) for specific substance dependence diagnoses (Bucholz 
et al., 1994), and has been used successfully in studies with NA populations (Wall et al., 
2003). The SSAGA uses a screening question asking whether participants have smoked 100 
cigarettes in their lifetime. Participants who respond negatively are designated as non-
smokers, not administered the full tobacco use section, and classified as not meeting criteria 
for ND. Thus, while ND diagnoses could be assigned to all participants, regardless of 
smoking history, CPD was only assessed in the limited number of individuals who endorsed 
smoking at least 100 cigarettes in their lifetime. Nonetheless, previous studies have reported 
substantial genetic correlations between ND and CPD (Vink et al., 2009), and thus, the ND 
diagnosis (coded 0/1) was used as the primary phenotype in the present study.
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2.4. Sequencing
Blood derived DNA was sequenced using Illumina low-coverage whole genome sequencing 
using HiSeq2000 sequencers (Illumina, San Diego, CA). Approximately 80% of the samples 
were sequenced at a coverage depth between 3X and 12X (full range of coverage depth: 1X 
- 31X) with coverage depth evenly distributed across the genome. Sequence reads were 
aligned using blocked multiple-sequence alignment (BMA), and realigned near indels with 
the Genome Analysis Toolkit (GATK). Variants were called using the LD-aware variant 
caller Thunder (Li, 2011) to increase the accuracy of the variant calls. Variant call quality 
was assessed through comparison of the sequencing results to exome array genotypes 
(Affymetrix Exome 1A microarray) for all subjects, resulting in a 97.5% concordance rate. 
The general methodology for the sequencing and advantages of using the LD-aware variant 
calls in this sample have been reported previously (Bizon et al., 2014).
The TAG consortium meta-analytic data corresponded to build 36 (hg18) of the NCBI 
reference assembly (TAG, 2010), and chromosomal coordinates for these SNPs were 
converted to assembly build NCBI37 (hg19) by using the UCSC liftOver tool (http://
genome.ucsc.edu/cgi-bin/hgLiftOver). The appropriate tables provided by dbSNP were used 
to confirm strand orientation across builds, as well as identify and merge variants with 
multiple dbSNP rsIDs (RsMergeArch; http://www.ncbi.nlm.nih.gov/SNP/
snp_db_table_description.cgi?t=RsMergeArch) or remove variants identified as having 
mapping errors (SNPChrPosOnRef: http://www.ncbi.nlm.nih.gov/SNP/
snp_db_table_description.cgi?t=SNPChrPosOnRef). Concordance of strand alignment and 
allele coding was then confirmed by comparing the hg19 liftOver results for the non-
ambiguous TAG consortium SNPs (i.e., excluding A/T and C/G SNPs) with the European 
cohort of the 1000 Genomes Project (1KGP) and with the NA target sample whole-genome 
sequence data. This comparison did not identify any errors in strand alignment or allele 
codings across datasets, indicating the conversion from build hg18 to hg19 was successful. 
Thus, all SNPs from the TAG consortium GWAS meta-analysis (including A/T and C/G 
SNPs) were retained for PRS construction.
2.5. Ancestry estimations
Ancestry proportions in the sample were analyzed using a supervised clustering approach 
that combined the algorithm implemented in the ADMIXTURE software (Alexander et al., 
2009) in conjunction with a reference panel containing genotype information at about 300k 
strand-unambiguous SNPs. The ancestry estimates were then further refined through a noise 
reduction approach via bootstrapping (Libiger and Schork, 2012) and identified as 
corresponding to the four major continental populations: African, East Asian, European, and 
NA.
2.6. Data Analysis
The data analysis process was composed of three steps: (1) calculate LD statistics for SNPs 
included in the TAG meta-analysis using genotype data from the European cohort of the 
1KGP (The 1000 Genomes Project [1KGP] Consortium, 2012), and use these statistics to 
create a set of independent markers, (2) match resulting independent TAG SNPs with NA 
sequence data, and (3) calculate CPD-based PRSs in the NA sample and conduct association 
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analyses to predict ND using linear mixed models in the lrgpr software package (Hoffman et 
al., 2014) as described below.
The initial TAG dataset contained 2,459,119 markers with summary statistics, including p-
values, beta coefficients, and risk alleles for each marker. After removing markers with p-
values >0.50, the remaining 1,257,959 SNPs were matched to the European-ancestry cohort 
of the 1KGP (1KGP Consortium, 2012), yielding 1,244,893 SNPs. Genotype data for these 
SNPs from the 1KGP were used along with the p-values from the TAG consortium GWAS to 
conduct LD-based pruning in PLINK 1.07 in order to extract the most highly significant, 
independent TAG markers from groups of correlated SNPs. This pruning procedure was 
conducted with seven different significance thresholds for index SNPs, ranging from p ≤ 
0.01 to p ≤ 0.5. In this way, the most highly significant independent SNPs with a p-value less 
than or equal to each of the specified LD thresholds were identified and selected for the 
calculation of PRSs.
The resulting dataset of TAG SNPs following the LD-based clumping procedures contained 
255,762 SNPs when the p-value threshold was set to ≤ 0.5; matches for these SNPs in the 
NA sample were identified, yielding a final dataset of 240,040 SNPs. PRSs were then 
generated using these markers in the NA sample for each of the seven significance 
thresholds used to run the LD-based clumping procedures. Individual PRSs were calculated 
by summing the number of TAG risk alleles (0, 1, or 2) at each marker included in the 
significance threshold, weighted by the SNP’s regression coefficient from the TAG meta-
analysis. These seven sets of PRSs were then used in family-based genetic association 
analyses in lrgpr (Hoffman et al., 2014) to predict ND in the NA target sample. Similar to 
many packages that conduct genetic association analyses, lrgpr uses a linear mixed model 
approach that includes the pairwise genetic similarity between all participant pairs 
approximated from genotyped markers as a random effect to account for population 
structure and genetic relatedness. Covariates included sex, age, age-squared, and ancestry 
estimates. The main effects of PRS and percent NA ancestry were tested first for association 
with liability for ND. Subsequent models included the interaction of PRS and percent NA 
ancestry in order to evaluate whether NA ancestry moderated the effects of PRS on liability 
for ND.
3. RESULTS
The variance in ND explained by the seven sets of risk scores ranged from 0.0–0.3% (see 
Table 1 for complete results). Notably, the main effect of the PRS created using a p-value 
inclusion threshold of 0.01 on ND was qualified by a significant interaction with percent NA 
ancestry (p=0.019; Table 2), and this model accounted for 2.2% of the variation in liability 
for ND, which is similar in magnitude to previous reports investigating PRSs for smoking 
phenotypes (Meyers et al., 2013; Vink et al., 2014). In order to evaluate the direction of 
effect for this interaction, secondary analyses were conducted on the top and bottom thirds 
of the sample after partitioning on percent NA ancestry. Specifically, the sample was divided 
into three groups based on increasing percentages of NA ancestry: 0 to 33% (“low”), 34–
66% (“medium”), and 67–100% (“high”) NA ancestry. Results from these analyses indicated 
that, for individuals with the smallest proportion of NA ancestry (and therefore higher 
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proportion of European ancestry), the PRS for TAG SNPs associated with CPD at p ≤ 0.01 
was positively associated with liability for ND (BPRS=18.9, SE=2.18). In contrast, this 
association did not hold for individuals with the highest proportion of NA ancestry, and 
therefore the smallest proportion of European ancestry (BPRS=−1.97, SE=2.98; Fig. 1).
In order to assess whether variants included in the PRS showed differences in LD with 
surrounding variants as a function of proportion NA ancestry, a paired samples t-test was 
conducted to compare levels of LD between each SNP (with p<0.01) included in the PRS 
and its correlated SNPs that were identified and removed during the clumping procedure. 
These LD statistics were calculated separately within the top and bottom thirds of the NA 
sample. Mean levels of LD were significantly lower for individuals with the highest percent 
NA ancestry (M=0.041, SD=0.043), compared to individuals with the lowest percent NA 
ancestry (M=0.055, SD=0.078; t(65,534)=46.33, p<0.001).
4. DISCUSSION
The current study examined the ability of PRSs computed from a GWAS meta-analysis of 
CPD in European-ancestry individuals to predict liability for ND in a NA community 
sample. Risk scores for seven significance thresholds were derived from GWAS test 
statistics for CPD from the TAG Consortium (TAG, 2010). Each set of scores was used to 
predict liability for ND in a sample of individuals with varying proportions of NA ancestry. 
Though no significant main effects were observed, these negative findings were qualified, 
however, by a significant interaction between the PRS and percent NA ancestry in predicting 
ND diagnostic status. Specifically, PRSs for CPD were positively associated with liability 
for ND in higher European-ancestry individuals, and who were therefore more similar in 
ethnic composition to the discovery sample. In contrast, this relation was not observed in 
higher NA-ancestry individuals, suggesting that the predictive ability of PRSs derived in a 
predominantly European-ancestry population may not generalize to individuals with higher 
proportions of NA ancestry. These findings underscore the need to validate measures of 
cumulative genetic risk generated from European-ancestry individuals in other racial and 
ethnic minority populations. If—as observed in the present study—European-ancestry risk 
scores do not generalize to other ancestral groups, adequately powered primary studies (i.e., 
GWASs) conducted in these other ancestral groups will be necessary to identify the 
contributions of individual variants and their patterns of LD with nearby markers before 
valid PRSs can be constructed for these groups. Given that substance use rates differ across 
ancestral groups, and health consequences may disproportionately affect specific 
individuals, these primary studies will also help reduce disparities in what is known about 
genetic risk factors that contribute to these behaviors in the larger population.
Notably, the lack of predictive power for the PRS among individuals with high NA ancestry 
appears to have resulted from differences in patterns of LD between NA and European-
ancestry individuals. As described, an initial step in creating PRSs involves pruning markers 
in high LD, so that each locus is tagged by a single variant. If the pattern of LD differs 
between the discovery sample and the validation sample, a selected variant that tags a 
specific region in the discovery sample may not effectively tag that region in the validation 
sample. Consistent with this interpretation, our results demonstrated that in the subset of 
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participants with the highest degree of NA ancestry (compared to the subset with the highest 
degree of European ancestry), SNPs included in the PRS showed lower LD with the 
corresponding markers they were shown to tag during the pruning procedure. This reduced 
LD was likely responsible for the lack of association between the PRS (for SNPs with 
p<0.01) and liability for ND in the highest percent NA-ancestry individuals. Thus, the 
present study lends support to arguments suggesting critical information is lost when a 
pruning approach is used to create PRSs (Vilhjálmsson et al., 2015; Wray et al., 2014).
Alternative methods have recently been developed in order to address this limitation. These 
include MultiPRS, which improves prediction accuracy by conducting LD pruning 
separately in discovery samples of different ancestral groups and then creating a PRS in the 
target sample that is the linear combination of these ancestry-specific PRSs conditional on 
the individual’s own ancestral background (Márquez-Luna et al., 2016). A second method, 
LDpred, allows for correlated loci in the discovery sample and improves prediction accuracy 
in two ways: it models the underlying genetic architecture and estimates causal effects sizes 
for each variant using Bayesian priors, and uses a reference panel to account for LD between 
associated markers (Vilhjálmsson et al., 2015). The applicability of LDpred for the current 
study was limited by the small size and extent of admixture present in the target sample, but 
simulations have demonstrated it represents an improvement over pruning approaches 
(Vilhjálmsson et al., 2015). The present report provides an empirical demonstration of why it 
is critical to consider the impact of differences in LD between discovery and target datasets.
A number of limitations of the current study warrant consideration. First, our target sample 
size was fairly small, and although we were able to represent a wide range of NA ancestry 
proportions, the relatively small number of individuals may have limited power to detect 
effects across all p-value thresholds. Nonetheless, the PRS explained a proportion of 
variance in liability for ND comparable to other smoking phenotypes previously reported 
using larger samples (Meyers et al., 2013; Vink et al., 2014), and a power analysis indicated 
the current study was adequately powered (0.82) to detect comparable effect sizes (i.e., 
R2=0.03). The final model, which included the interaction of the PRS for SNPs with p<0.01 
and percent NA ancestry, explained 2.2% of the variance in liability for ND. A post-hoc 
power analysis indicated that with a sample size of N=288, there was still reasonable power 
(0.72) to detect an effect size equivalent to that of the current study (R2=0.022). Second, the 
present report relied on ND diagnosis rather than CPD to evaluate the predictive power of 
the PRS. It is possible that the results may have differed if we were able to use the same 
CPD phenotype was used to generate the PRS. Nonetheless, previous studies have 
demonstrated a strong genetic correlation between ND and CPD (Vink et al., 2009), 
suggesting the results would likely be similar across phenotypes.
Despite these limitations, the present study is the first study to apply PRSs derived from 
SNPs in a predominantly European-ancestry cohort to a sample composed of individuals 
with varying proportions of NA ancestry. The results suggested that the PRSs might not hold 
as much predictive accuracy in target samples whose patterns of LD differ from the 
discovery cohort. This has important implications for future studies that intend to use 
cumulative measures of risk to predict phenotypes, given that individuals of European 
ancestry are overrepresented in most large-scale GWASs that typically serve as SNP 
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discovery datasets. Future investigations might employ newer methods that are able to 
incorporate more accurate measures of LD from the target population, (MultiPRS; Márquez-
Luna et al., 2016), or data from all markers rather than relying on LD-based pruning, 
(LDpred; Vilhjálmsson et al., 2015), and evaluate how these methods perform across 
different ancestral populations that differ in their pattern of linkage disequilibrium.
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Highlights
• Polygenic risk scores (PRS) represent additive effects of common 
genetic variants
• PRS for cigarettes per day (CPD) were derived from European ancestry 
GWAS data
• PRS predicted liability for nicotine dependence (ND) in European 
ancestry subjects
• PRS did not predict liability for ND in Native American ancestry 
subjects
• Model linkage disequilibrium when creating PRS with different 
ancestral populations
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Fig. 1. 
Moderating effect of percent Native American ancestry on the relation between polygenic 
risk score (for SNPs with p ≤ 0.01) and nicotine dependence diagnosis
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Table 2
Linear mixed model analysis of the effects of polygenic risk score and percent Native American ancestry on 
liability for nicotine dependence diagnosis.
Variable Β SE t p
Model with main effects of percent Native American ancestry and polygenic risk score
(SNPs with p ≤0.01)
Sex −0.11 5.61e-02 −1.96 0.0500
Age 0.02 9.09e-03 2.59 0.0096
Age-squared −2.66e-04 1.12e-04 −2.39 0.0170
European ancestry 0.56 4.44e-01 1.26 0.2083
African ancestry 0.13 6.37e-01 0.20 0.8423
Native American ancestry 0.11 4.48e-01 0.24 0.8085
PRS for SNPs p ≤ 0.01 11.56 1.17 0.99 0.3208
Model with main effects of percent Native American ancestry and polygenic risk score and
their interaction (SNPs with p ≤ 0.01)
Sex −9.83e-02 5.58e-02 −1.76 0.0783
Age 2.34e-02 9.00e-03 2.59 0.0095
Age-squared −2.64e-04 1.11e-04 −2.39 0.0168
European ancestry 5.07e-01 4.40e-01 1.15 0.2495
African ancestry −2.04e-02 6.34e-01 −0.03 0.9743
Native American ancestry −5.64 2.49 −2.26 0.0237*
PRS for SNPs p ≤ 0.01 7.05 2.77 2.55 0.0109*
Native American ancestry x PRS
(p ≤ 0.01)
−1.31 5.60 −2.34 0.0191*
PRS: polygenic risk score; SNPs: single nucleotide polymorphisms
*p<0.05
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